UHN's Dr. Sivak Snares the MaRS Innovation-Lab150/Evotec Award For Treating Glaucoma.
Dr. Jeremy Sivak, Senior Scientist at the University Health Network (UHN)'s Krembil Research Institute snares the MaRS Innovation-LAB150/Evotec partnership award - the 1st ever at UHN and the 2nd ever under the partnership.
Dr. Sivak's project aims to develop a novel therapeutic approach to treat glaucoma, which is an irreversible neurodegenerative condition of the optic nerve; left untreated it can lead to blindness. Glaucoma affects 1.9% of the population over 40 years of age and it is the leading cause of permanent blindness with over 70 million people affect worldwide.
Dr. Sivak's team and collaborating scientists from the University of California at Berkeley (UC Berkeley) discovered a lipoxin with neuroprotective properties that has illustrated efficacy in preclinical glaucoma models. With the award, Dr. Sivak will now team up with Dr. Mark Reed, who is a medicinal chemist at the Krembil Research Institute, and with scientists at Evotec to identify a new class of potent, selective compounds that target the novel mechanism specifically and that will afford healthcare providers newer means to treat glaucoma patients.
To get the full story please click here: http://www.globenewswire.com/news-release/2018/10/04/1601314/0/en/LAB150-awards-its-second-drug-discovery-project-from-Canada-s-largest-research-based-Hospital-The-University-Health-Network-UHN.html .